Bicara Therapeutics Inc. (BCAX) Stock Forecast
BCAX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 14 analysts
- Price target
- $35.50 average of analyst targets
- Upside to target
- +111.6% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.84
- 52-week range
- $13.93 – $30.40
BCAX analyst ratings
14 analystsNumber of analysts at each rating.
BCAX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BCAX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.82 | −$0.97 | −$0.42 | −$0.67 | −22.6% | 12 |
| Current fiscal year (2026) | −$3.39 | −$3.68 | −$2.65 | −$2.52 | −34.4% | 12 |
| Next fiscal year (2027) | −$3.52 | −$4.73 | −$1.86 | −$3.39 | −3.9% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BCAX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 12 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 11 |
BCAX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BCAX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.85 | −$0.85 | −$0.82 | −$0.82 | −$0.82 | −3.2% | 7 up · 3 down |
| Current fiscal year (2026) | −$3.48 | −$3.48 | −$3.38 | −$3.39 | −$3.39 | −2.6% | 8 up · 3 down |
| Next fiscal year (2027) | −$3.63 | −$3.63 | −$3.47 | −$3.52 | −$3.52 | −3.1% | 7 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BCAX earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; BCAX beat in 1 of 9.
What analysts expect from BCAX
14 analysts cover Bicara Therapeutics; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.50, 111.6% above the latest close of $16.78. Analysts expect earnings of −$3.39 per share for 2026, −34.4% from a year earlier. For 2027 the average estimate is −$3.52 per share. Bicara Therapeutics beat the EPS estimate in 1 of the last 9 quarters.
Related: BCAX income statement, BCAX key metrics, BCAX chart. See the BCAX stock overview for the latest quote and news.
BCAX forecast FAQ
What is Bicara Therapeutics's price target?
The average analyst price target for Bicara Therapeutics is $35.50, 111.6% above the latest close of $16.78.
Is Bicara Therapeutics a buy, hold or sell?
Of 14 analysts covering Bicara Therapeutics, 10 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bicara Therapeutics's EPS forecast?
Analysts forecast −$3.39 per share for 2026 (range −$3.68 to −$2.65); for 2027 the estimate is −$3.52.
When does Bicara Therapeutics report earnings?
Bicara Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.84.
Does Bicara Therapeutics usually beat earnings estimates?
Bicara Therapeutics reported EPS at or above the analyst estimate in 1 of the last 9 quarters.